4629 related articles for article (PubMed ID: 6374238)
1. Plasminogen activators in human malignant melanoma.
Markus G; Kohga S; Camiolo SM; Madeja JM; Ambrus JL; Karakousis C
J Natl Cancer Inst; 1984 Jun; 72(6):1213-22. PubMed ID: 6374238
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator secretion of human tumors in short-term organ culture, including a comparison of primary and metastatic colon tumors.
Markus G; Camiolo SM; Kohga S; Madeja JM; Mittelman A
Cancer Res; 1983 Nov; 43(11):5517-25. PubMed ID: 6193874
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.
Camiolo SM; Greco WR
Cancer Res; 1986 Apr; 46(4 Pt 1):1788-94. PubMed ID: 3081257
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activator content and secretion in explants of neoplastic and benign human prostate tissues.
Camiolo SM; Markus G; Englander LS; Siuta MR; Hobika GH; Kohga S
Cancer Res; 1984 Jan; 44(1):311-8. PubMed ID: 6197164
[TBL] [Abstract][Full Text] [Related]
5. Immunoradiometric quantification of tissue plasminogen activator secreted by fetal organs. Comparison with urokinase.
Holmberg L; Kristoffersson AC; Lecander I; Wallén P; Astedt B
Scand J Clin Lab Invest; 1982 Jun; 42(4):347-54. PubMed ID: 6753100
[TBL] [Abstract][Full Text] [Related]
6. Localization of plasminogen activators in human colon cancer by immunoperoxidase staining.
Kohga S; Harvey SR; Weaver RM; Markus G
Cancer Res; 1985 Apr; 45(4):1787-96. PubMed ID: 3884145
[TBL] [Abstract][Full Text] [Related]
7. Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
De Vries TJ; Mooy CM; Van Balken MR; Luyten GP; Quax PH; Verspaget HW; Weidle UH; Ruiter DJ; Van Muijen GN
J Pathol; 1995 Jan; 175(1):59-67. PubMed ID: 7891228
[TBL] [Abstract][Full Text] [Related]
8. Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice.
de Vries TJ; Kitson JL; Silvers WK; Mintz B
Cancer Res; 1995 Oct; 55(20):4681-7. PubMed ID: 7553649
[TBL] [Abstract][Full Text] [Related]
9. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
[TBL] [Abstract][Full Text] [Related]
10. Molecular species of plasminogen activators secreted by normal and neoplastic human cells.
Wilson EL; Becker ML; Hoal EG; Dowdle EB
Cancer Res; 1980 Mar; 40(3):933-8. PubMed ID: 7193517
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of human tumor cell-associated fibrinolysis by vascular bovine smooth muscle cells.
Laug WE
J Natl Cancer Inst; 1985 Aug; 75(2):345-52. PubMed ID: 3860687
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors.
Kirchheimer JC; Pflüger H; Ritschl P; Hienert G; Binder BR
Invasion Metastasis; 1985; 5(6):344-55. PubMed ID: 4066206
[TBL] [Abstract][Full Text] [Related]
14. Immunological characterization of plasminogen activator activities in human tissues and body fluids.
Rijken DC; Wijngaards G; Welbergen J
J Lab Clin Med; 1981 Apr; 97(4):477-86. PubMed ID: 6782183
[TBL] [Abstract][Full Text] [Related]
15. Enzyme-linked immunosorbent assay for human urokinase-type plasminogen activator and its proenzyme using a combination of monoclonal and polyclonal antibodies.
Nielsen LS; Grøndahl-Hansen J; Andreasen PA; Skriver L; Zeuthen J; Danø K
J Immunoassay; 1986; 7(3):209-28. PubMed ID: 3091639
[TBL] [Abstract][Full Text] [Related]
16. Purification and characterization of the plasminogen activator secreted by a rat brain tumor cell line in culture.
Bykowska K; Rijken DC; Collen D
Thromb Haemost; 1981 Oct; 46(3):642-4. PubMed ID: 7198301
[TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.
Hofmann R; Lehmer A; Buresch M; Hartung R; Ulm K
Cancer; 1996 Aug; 78(3):487-92. PubMed ID: 8697395
[TBL] [Abstract][Full Text] [Related]
18. Tumor growth and metastases in malignant disease. A review.
Kwaan HC
J Med; 1988; 19(3-4):179-91. PubMed ID: 3141546
[TBL] [Abstract][Full Text] [Related]
19. Purification of human tissue-type plasminogen activator in centigram quantities from human melanoma cell culture fluid and its conditioning for use in vivo.
Collen D; Rijken DC; Van Damme J; Billiau A
Thromb Haemost; 1982 Dec; 48(3):294-6. PubMed ID: 6891842
[TBL] [Abstract][Full Text] [Related]
20. Retinoic acid modulates extracellular urokinase-type plasminogen activator activity in DU-145 human prostatic carcinoma cells.
Waghray A; Webber MM
Clin Cancer Res; 1995 Jul; 1(7):747-53. PubMed ID: 9816041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
